1st Quarter - Report — ALERE INC. for ALERE INC. (2015)

Firm

ALERE INC.

Client

ALERE INC.

Income

—

Expenses

$150,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Rapid diagnostic testing to combat antibiotic resistant bacteria Implementation of the laboratory payment provision of the Protecting Access to Medicare Act of 2014, P.L. 113-93 H.R. 771, Protecting Access to Diabetes Supplies Act of 2015 Medicare reimbursement for rapid point-of-care testing

Lobbyist	Covered position, as disclosed
SETH M RADUS	—

Contacted: Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 771 (114th)

Health Issues HCR

FDA regulation of in-vitro diagnostic testing Importance of diagnostic testing to combat growth in antibiotic resistant bacteria

Lobbyist	Covered position, as disclosed
SETH M RADUS	—

Contacted: SENATE; Office of Science & Technology Policy (OSTP); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.